George Chang - Ivoryton CT Ernest S. Hamanaka - Gales Ferry CT John L. LaMattina - Ledyard CT
Assignee:
Pfizer Inc - New York NY
International Classification:
A61K 314439
US Classification:
514343, 5462764
Abstract:
This invention relates to mutual prodrugs of amlodipine and atorvastatin and to pharmaceutical compositions thereof. This invention also relates to methods of treating angina pectoris, atherosclerosis, and hypertension and hyperlipidemia in a mammal using those prodrugs and compositions. This invention also relates to methods of managing cardiac risk in a mammal, including humans, presenting with symptoms of cardiac risk by administering those prodrugs and compositions.
N-[(Substituted Five-Membered Di- Or Triaza Diunsaturated Ring)Carbonyl] Guanidine Derivatives For The Treatment Of Ischemia
Ernest S. Hamanaka - Gales Ferry CT Angel Guzman-Perez - Stonington CT Roger B. Ruggeri - Waterford CT Ronald T. Webster - Ledyard CT Christian J. Mularski - Chester CT
NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.
4,1-Benzoxazepines Or 4,1-Benzothiazepines And Their Use As Squalene Synthetase Inhibitors
This invention relates to certain benzoxazepinones and benzothiazepinones useful as hypocholesterolemic agents, hypotriglyceridemic agents, antiatherosclerosis agents, antifungal agents, anti-Alzheimers agents or anti-acne agents.
Use Of Corticotropin Releasing Factor Antagonists And Related Compositions
The present invention relates to compositions and methods of achieving a therapeutic effect including, the treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist.
Use Of Corticotropin Releasing Factor Antagonists And Related Compositions
The present invention relates to compositions and methods of achieving a therapeutic effect including, the treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist.
N-[(Substituted Five-Membered Di-Or Triaza Diunsaturated Ring) Carbonyl] Guanidine Derivatives For The Treatment Of Ischemia
Ernest S. Hamanaka - Gales Ferry CT, US Angel Guzman-Perez - Stonington CT, US Christian J. Mularski - Chester CT, US Roger B. Ruggeri - Waterford CT, US Ronald T. Wester - Ledyard CT, US
NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.
Peter Bertinato - Old Lyme CT, US Michel A. Couturier - Pawcatuck CT, US Ernest S. Hamanaka - Gales Ferry CT, US Marcus D. Ewing - Colchester CT, US Ralph P. Robinson - Gales Ferry CT, US Derek L. Tickner - Waterford CT, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
C07D 215/38 C07D 215/46 A61K 31/47
US Classification:
546162, 546163, 514313
Abstract:
This invention relates to MTP/Apo-B secretion inhibitors of Formula (I).
Peter Bertinato - Old Lyme CT, US Michel A. Couturier - Pawcatuck CT, US Ernest S. Hamanaka - Gales Ferry CT, US Marcus D. Ewing - Colchester CT, US Ralph P. Robinson - Gales Ferry CT, US Derek L. Tickner - Waterford CT, US
Assignee:
Pfizer, Inc. - New York NY
International Classification:
C07D 215/38 A61K 31/47
US Classification:
546156, 514312
Abstract:
This invention relates to MTP/Apo-B secretion inhibitors of Formula (I).